Johnson & Johnson Reports Phase 3 extension Data for Lecanemab in Renal cell carcinoma

Johnson & Johnson today announced Phase 3 extension results for lecanemab in patients with renal cell carcinoma. The study demonstrated that lecanemab demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of renal cell carcinoma and support the continued development of lecanemab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.